Concentra Group
CON
36.40
0.00
0.00%
Concentra Group
US · CON
#2185 by market cap
Listed 2024
36.40
0.00
0.00%
Live - 5344 symbols - heartbeat 349s ago
· 2026-10-07 19:54
After-hours
36.40
0.00%
- Market cap
- 4.64B
- P/E (TTM)i
- 23.48
- P/Bi
- 9.73
- EPSi
- 1.30
- Div yieldi
- 0.69%
- 52W posi
- 98%
Reader sentiment
Are you bullish or bearish on CON?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Mixed / stable
- The number of reporting institutions decreased by 2 in the most recent period (2026/Q3).
- Total institutional ownership (as a % of shares) was little changed.
Institutional ownership
- Held by institutions
- 91.49% +0.03pp
- Institutions
- 352 -2
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund78.38%
Individual/Insider6.99%
Hedge Fund4.73%
Private Company3.12%
Public Company1.99%
Sovereign Wealth Fund1.35%
Government Pension Fund0.99%
Insurance Company0.76%
Family Office/Trust0.12%
Other1.58%
Top holders as of 2026-06-30
T. Rowe Price Group, Inc.
15.75% · 20.08M sh
BlackRock
13.92% · 17.75M sh
Vanguard Portfolio Management, LLC
5.35% · 6.82M sh
Robert Ortenzio
5.21% · 6.65M sh
Vanguard Capital Management, LLC
4.69% · 5.98M sh
State Street Global Advisors
3.80% · 4.84M sh
Estate Of Rocco A. Ortenzio
2.57% · 3.27M sh
Jennison Associates LLC
2.55% · 3.26M sh
Dimensional Fund Advisors
2.53% · 3.23M sh
Geode Capital Management, LLC
2.43% · 3.10M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 26 buys · 24 sells
| Name | Role | Stake |
|---|---|---|
| Robert Ortenzio | Chairperson | 5.21% |
| William Newton | Chief Executive Officer | 0.38% |
| Matthew DiCanio | President | 0.27% |
| Thomas Devasia | Executive VP and Chief Marketing & Innovation Officer | 0.09% |
| Douglas McAndrew | Executive VP & COO of West | 0.09% |
| Timothy Ryan | Executive VP & Chief Legal Counsel | 0.09% |
| Su Nelson | Chief Accounting Officer | 0.09% |
| Jonathan Conser | Executive VP and Chief Growth & Customer Officer | 0.09% |
| Gregory Gilbert | Executive VP, Chief Reimbursement & Government Relations Officer | 0.09% |
| John deLorimier | Executive VP and Chief Digital & Data Officer | 0.09% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-20 | Robert Ortenzio | Chairperson | Sale to Issuer | -1,000,000 | $34.65 |
| 2026-08-02 | Robert Ortenzio | Chairperson | Open Market Disposition | -130,000 | $31.84 |
| 2026-06-30 | Robert Ortenzio | Chairperson | Open Market Disposition | -130,000 | $30.50 |
| 2026-06-29 | Robert Ortenzio | Chairperson | Intent to Sell (Form 144) | -944 | $29.41 |
| 2026-06-28 | Robert Ortenzio | Chairperson | Intent to Sell (Form 144) | -5,589 | $29.85 |
| 2026-06-25 | Robert Ortenzio | Chairperson | Intent to Sell (Form 144) | -53,527 | $29.64 |
| 2026-05-31 | Robert Ortenzio | Chairperson | Open Market Disposition | -130,000 | $25.00 |
| 2026-05-07 | Robert Ortenzio | Chairperson | Open Market Disposition | -130,000 | $25.00 |
| 2025-12-16 | William Newton | Chief Executive Officer | Other Acquisition | +89,081 | -- |
| 2025-12-16 | William Newton | Chief Executive Officer | Other Disposition | -89,081 | -- |
| 2025-11-25 | Su Nelson | Chief Accounting Officer | Sale to Issuer | -5,903 | $21.04 |
| 2025-11-25 | Gregory Gilbert | Executive VP, Chief Reimbursement & Government Relations Officer | Sale to Issuer | -5,903 | $21.04 |
| 2025-11-25 | John deLorimier | Executive VP and Chief Digital & Data Officer | Sale to Issuer | -6,428 | $21.04 |
| 2025-11-25 | Timothy Ryan | Executive VP & Chief Legal Counsel | Sale to Issuer | -5,903 | $21.04 |
| 2025-11-25 | John Anderson | Chief Medical Officer | Sale to Issuer | -6,540 | $21.04 |
| 2025-11-25 | Thomas Devasia | Executive VP and Chief Marketing & Innovation Officer | Sale to Issuer | -5,903 | $21.04 |
| 2025-11-25 | Matthew DiCanio | President | Sale to Issuer | -17,708 | $21.04 |
| 2025-11-25 | Michael Kosuth | Executive VP & COO of East | Sale to Issuer | -6,449 | $21.04 |
| 2025-11-25 | Giovanni Gallara | Executive VP & Chief Clinical Services Officer | Sale to Issuer | -6,563 | $21.04 |
| 2025-11-25 | Douglas McAndrew | Executive VP & COO of West | Sale to Issuer | -5,903 | $21.04 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.